Form 4: Citius Oncology Director Acquires 125,000 Stock Options

A Citius Oncology director, Robert Joseph Smith, was granted 125,000 stock options on December 12, 2024, which will vest after one year of continuous service.

Summary

• Robert Joseph Smith, a director at Citius Oncology, Inc., was granted 125,000 stock options on December 12, 2024.
• The options have an exercise price of $1.07 per share.
• These options will vest 100% on December 12, 2025, provided Mr. Smith continues to provide service to the company.
• The options expire on December 12, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There is no indication of any negative or unexpected events.

Positives

• The grant of stock options to a director aligns their interests with the company's long-term success.
• The vesting period encourages continued service and commitment from the director.

Future Outlook

The director's stock options will vest in one year, provided they continue to provide service to the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the company's performance.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the biotechnology industry.
• Vesting periods of one year are common for such grants, ensuring continued service and commitment.
• The exercise price of $1.07 is specific to Citius Oncology's stock price at the time of the grant.

Stakeholder Impact

• The stock option grant may have a positive impact on shareholder confidence by aligning director interests with company performance.

Key Dates

Keywords

stock options, director, Citius Oncology, CTOR, equity, vesting, insider trading